{"id":2130,"date":"2024-10-30T12:38:02","date_gmt":"2024-10-30T17:38:02","guid":{"rendered":"https:\/\/arc-group.com\/gelteq-limited-ipo-nasdaq\/"},"modified":"2025-01-23T11:59:23","modified_gmt":"2025-01-23T16:59:23","slug":"gelteq-limited-ipo-nasdaq","status":"publish","type":"post","link":"https:\/\/arc-group.com\/gelteq-limited-ipo-nasdaq\/","title":{"rendered":"Alarar Capital Group Announces Successful IPO of Gelteq Limited on Nasdaq"},"content":{"rendered":"

Alarar Capital Group is pleased to announce its role as the financial advisor to Gelteq Limited (“Gelteq”),<\/strong> a pioneering biotechnology firm, in its initial public (IPO) offering on Nasdaq. Gelteq has priced its IPO of 1,300,000 ordinary shares at US$4.00 per share, yielding gross proceeds of US $5.2 million. Trading commenced yesterday on Nasdaq on October 29, 2024, under the ticker symbol “GELS.”<\/p>\n

About Gelteq Limited<\/h2>\n

Gelteq, based in Melbourne, Australia, specializes in the development of ingestible gel technology designed to improve the delivery of nutrients and pharmaceuticals. The funds raised will support the Company\u2019s continued investment in manufacturing, marketing, and R&D initiatives aimed at advancing its innovative gel-based delivery solutions across key industries, including pharmaceuticals, nutraceuticals as well as animal health.<\/p>\n

“This IPO marks an exciting milestone for Gelteq as it enters the global public markets. It has been an honor to work alongside Gelteq\u2019s team, and we are thrilled to have supported them in reaching this significant achievement,\u201d said Jes\u00fas Hoyos, Managing Partner at Alarar Capital Group. \u201cGelteq\u2019s platform has the potential to revolutionize drug delivery systems, and we look forward to seeing the Company\u2019s continued success as it scales.\u201d<\/p>\n

Alarar Capital Group is proud to have served as Gelteq\u2019s financial advisor in this transaction.<\/p>\n

Jes\u00fas Hoyos, Managing Partner at Alarar Capital Group, added, \u201cThis transaction highlights the value Alarar Capital Group brings to emerging growth companies seeking access to international capital markets. Gelteq is at the forefront of its field, and we are proud to have been part of their journey to Nasdaq.\u201d<\/p>\n

About Alarar Capital Group<\/h2>\n

Alarar Capital Group is a globally based, full-service financial institution, specializing in bridging Asia and the West. Our services encompass a full spectrum of financial solutions, including IPOs, M&A, financing, venture capital, and SPACs. Alarar Capital Group also includes an independent consulting division dedicated to addressing the unique challenges faced by companies operating across both Asian and Western markets. Headquartered in Hong Kong, with offices across Mainland China, the USA, Malaysia, Indonesia, Vietnam, India, Sweden, and the UAE, we are well-positioned to provide cross-border financial and advisory services.<\/p>\n

Our commitment to anticipating market trends and delivering client-centered solutions has earned Alarar Capital Group the Frost & Sullivan 2024 Company of the Year Award in the Asian mid-market investment advisory sector.<\/p>\n

For more information or any questions, please contact:<\/h3>\n

Jes\u00fas Hoyos
\nManaging Partner
\njesus.hoyos@arc-group.com<\/a><\/p>\n

For media inquiries, please contact:<\/h3>\n

Anna Sahlberg Carlsson
\nMarketing Manager
\nanna.sahlberg@arc-group.com<\/a><\/p>\n

\n

Ready to talk to one of our experts?<\/strong><\/h3>\n

Contact us here<\/a><\/strong> for all your capital markets<\/strong> and M&A<\/strong> needs.<\/p>\n

Not quite ready for an IPO yet? Our consulting division is here<\/a><\/strong> to help you prepare for the future.<\/p>\n

Get in touch to explore how we can support your growth journey.<\/strong><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Alarar Capital Group is pleased to announce its role as the financial advisor to Gelteq Limited (“Gelteq”), a pioneering biotechnology firm, in its initial public (IPO) offering on Nasdaq. Gelteq has priced its IPO of 1,300,000 ordinary shares at US$4.00 per share, yielding gross proceeds of US $5.2 million. Trading commenced yesterday on Nasdaq on October […]<\/p>\n","protected":false},"author":3,"featured_media":2131,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[20],"tags":[],"news_type":[41],"class_list":["post-2130","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","news_type-news"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/arc-group.com\/wp-json\/wp\/v2\/posts\/2130","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/arc-group.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/arc-group.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/arc-group.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/arc-group.com\/wp-json\/wp\/v2\/comments?post=2130"}],"version-history":[{"count":1,"href":"https:\/\/arc-group.com\/wp-json\/wp\/v2\/posts\/2130\/revisions"}],"predecessor-version":[{"id":6295,"href":"https:\/\/arc-group.com\/wp-json\/wp\/v2\/posts\/2130\/revisions\/6295"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/arc-group.com\/wp-json\/wp\/v2\/media\/2131"}],"wp:attachment":[{"href":"https:\/\/arc-group.com\/wp-json\/wp\/v2\/media?parent=2130"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/arc-group.com\/wp-json\/wp\/v2\/categories?post=2130"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/arc-group.com\/wp-json\/wp\/v2\/tags?post=2130"},{"taxonomy":"news_type","embeddable":true,"href":"https:\/\/arc-group.com\/wp-json\/wp\/v2\/news_type?post=2130"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}